drugset

drugset / Trial / NCT05453669

Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

NCT05453669 ↗

Phase 1 Unknown 12 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University Zhejiang Ruijiamei Biotechnologies, Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of CD19-CAR-DNT cells infusion in subjects with relapsed/refractory B-cell non-Hodgkin's Lymphoma

Timeline

Start: 2022-06-15
Primary completion: 2024-06
Completion: 2025-06

Publications

Xiao X, Liu H, Qiu X, Chen P, Li X, Wang D, Song G, Cheng Y, Yang L, Qian W. CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study. EClinicalMedicine. 2024 Feb 29;70:102516. doi: 10.1016/j.eclinm.2024.102516. eCollection 2024 Apr.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19-CAR-DNT Cells	Cell therapy	1 cells/kg	—
Subject	CD19-CAR-DNT Cells	Cell therapy	3 cells/kg	—
Subject	CD19-CAR-DNT Cells	Cell therapy	9 cells/kg	—

Indications